Desvenlafaxine n=15 n (%)

Ketoconazole n=15 n (%)

Desvenlafaxine + Ketoconazole n=15 n (%)

Any adverse event, n (%)

15 (100)

1 (6.7)

15 (100)

Somnolence

8 (53.3)

0

12 (80.0)

Insomnia

7 (46.7)

0

6 (40.0)

Myadriasis

7 (46.7)

0

8 (53.3)

Dizziness

6 (40.0)

0

9 (60.0)

Nausea

6 (40.0)

0

11 (73.3)

Impotence

3 (20.0)

0

2 (13.3)

Yawn

3 (20.0)

0

2 (13.3)

Asthenia

2 (13.3)

0

0

Headache

1 (6.7)

1 (6.7)

5 (33.3)

Muscle spasms

1 (6.7)

0

2 (13.3)

Tongue discoloration

1 (6.7)

0

3 (20.0)

Vasodilatation

1 (6.7)

0

3 (20.0)

Vomiting

1 (6.7)

0

2 (13.3)

Dry mouth

0

0

4 (26.7)

Nervousness

0

0

3 (20.0)

Tremor

0

0

3 (20.0)

Table 4: Treatment-emergent adverse events observed in ≥ 2 subjects during study 1.
Goto home»